688266 泽璟制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)45.292-13.961-9.549-23.293-46.775
总资产报酬率 ROA (%)19.004-5.455-4.679-12.231-26.789
投入资产回报率 ROIC (%)21.334-6.269-5.313-14.257-33.181

边际利润分析
销售毛利率 (%)97.01490.42193.05992.44191.346
营业利润率 (%)69.836-20.730-29.091-77.058-160.618
息税前利润/营业总收入 (%)69.655-24.466-34.567-81.244-165.924
净利润/营业总收入 (%)69.872-20.374-28.201-76.373-160.601

收益指标分析
经营活动净收益/利润总额(%)100.206127.734125.086131.168107.252
价值变动净收益/利润总额(%)0.093-0.712-4.423-4.910-1.349
营业外收支净额/利润总额(%)-0.0820.3800.0030.4350.491

偿债能力分析
流动比率 (X)2.3601.7111.8762.2201.772
速动比率 (X)2.2271.5901.7422.1231.636
资产负债率 (%)53.55563.61158.31143.03052.797
带息债务/全部投入资本 (%)32.03043.88838.95432.74934.824
股东权益/带息债务 (%)160.43194.792123.730192.701165.078
股东权益/负债合计 (%)86.72257.20571.567131.43086.183
利息保障倍数 (X)-564.0486.6906.31421.10836.770

营运能力分析
应收账款周转天数 (天)16.70865.41182.55988.55990.121
存货周转天数 (天)585.071825.7111,429.2071,292.9411,038.189